ZE 132

Key Product Details

Product Description

ZE 132 binds to programmed cell death-ligand 1 (PD-L1) with high affinity (K_D = 19.36 nM); it potently and selectively inhibits the interaction between programmed cell death-1 (PD-1) and PD-L1 (IC₅₀ = 23.49 nM). ZE 132 promotes CD8⁺ T cell activation and improves the in vitro cytotoxic killing activity of T-cells. ZE 132 treatment can increase Cxcl9 mRNA expression and lower Tgfb1 mRNA expression in CT26 mouse colorectal cancer model. ZE 132 shows antitumor effects, inhibiting growth of CT26 tumors in mice by 64%.

Product Specifications for ZE 132

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for ZE 132

The following data is based on the product molecular weight 721.27.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.39 mL	6.93 mL	13.86 mL
5 mM	0.28 mL	1.39 mL	2.77 mL
10 mM	0.14 mL	0.69 mL	1.39 mL
50 mM	0.03 mL	0.14 mL	0.28 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Liu Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy. Br.J.Pharmacol. 2021 PMID: 33768523

Product Documents for ZE 132